ASSESSING THE EFFECTIVENESS AND SAFETY OF LOW-DOSE ORAL MINOXIDIL IN ANDROGENETIC ALOPECIA: A 24-WEEK CLINICAL STUDY

Background: Low-dose oral minoxidil (LDOM- MINOGAIN) has emerged as an alternative treatment for hair loss, demonstrating potential efcacy in promoting hair growth. This study aimed to evaluate the effectiveness and safety prole of OM over a 24-week period. Materials & Methods: A total of 50 participants (mean age: 30.76 ± 7.71 years; 70% male, 30% female) were enrolled. Hair counts and blood pressure measurements were recorded at baseline, 12 weeks, and 24 weeks. Statistical analysis was performed using the z-test to determine signicant differences. Hair count increased signicantly from baseline (249.7 ± 64.3) to 12 weeks (266.8 ± 61 Results: , p < 0.001) and further at 24 weeks (279.3 ± 65.3, p < 0.001). The mean difference between 12 and 24 weeks (12.46, p = 0.003) conrmed continuous hair growth. Systolic blood pressure decreased at 12 weeks (-2.64 mmHg, p < 0.001) and 24 weeks (-3.58 mmHg, p < 0.001), while diastolic blood pressure also showed a reduction at 12 weeks (-2.28 mmHg, p = 0.002) and 24 weeks (-2.68 mmHg, p < 0.001). Adverse effects included hypertrichosis (6%) and postural hypotension (2%). Low-dose OM effectively promotes hair growth with a mild reduction in blood press Conclusion: ure and minimal adverse effects. Further studies are needed to conrm long-term efcacy and safety